Top-News
Montag,
28.11.2016 19:01
von
PR Newswire
| Aufrufe: 303
New Data for Halaven® (eribulin) at SABCS 2016 Demonstrate Continued Potential in Treatment of Multiple Types of Locally Advanced or Metastatic Breast Cancer
Schriftzug "News" (Symbolbild).
pixabay.com
PR Newswire
HATFIELD, England, November 29, 2016
HATFIELD, England, November 29, 2016 /PRNewswire/ --
FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS
Eisai highlights 17 new data abstracts for eribulin in metastatic breast cancer at the San Antonio Breast Cancer Symposium (SABCS), San Antonio, USA, 6-10 December.
Eribulin is indicated in the European Union for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.[1]
"Eribulin has previously demonstrated a clinically meaningful overall survival benefit in two pivotal studies in advanced breast cancer and advanced sarcoma. Eisai remains fully committed to continue developing eribulin and we look forward to the presentation of these results at the SABCS," comments Gary Hendler Chief Commercial Officer, Global Oncology Business Group and Chairman & CEO EMEA.
The continued development of its oncology portfolio underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide. Eisai is committed to the therapeutic area of oncology and to address the unmet medical needs of people with cancer and their families.
Abstract Name
A phase II, open-label, multicentre, translational study for biomarkers of eribulin mesylate: evaluation of the utility of monitoring epithelial-to-mesenchymal transition (emt) markers on tumour cells in the malignant plural effusion of patients with metastatic breast cancer (expect-study)
Watanabe et al
Poster: OT1-01-01
Session Title: Ongoing Trials - Chemotherapy
Session Date: 7/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer
La Verde et al
Poster: OT1-01-05
Session Title: Ongoing Trials - Chemotherapy
Session Date: 7/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
PIQHASSO: Open label, non-randomised, multicentre phase I/IIb study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
López et al
Poster: OT1-01-06
Session Title: Ongoing Trials - Chemotherapy
Session Date: 7/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
A phase II study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer
Overmoyer et al
Poster: OT1-01-07
Session Title: Ongoing Trials - Chemotherapy
Session Date: 7/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
A phase II, multicentre, randomised trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy
Park et al
Poster: OT1-01-12
Session Title: Ongoing Trials - Chemotherapy
Session Date: 7/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer
Prat et al
Poster: P1-09-09
Session Title: Prognostic and Predictive Factors: Response Predictive Factors - Clinical Testing and Validation
Session Date: 7/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
A randomized, open-label, multicentre, phase Ib/II study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2-negative, high-hyaluronan metastatic breast cancer
Alvarez et al
Poster: OT2-02-02
Session Title: New Approaches and Agents
Session Date: 8/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
Eribulin induces vascular remodelling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab
Ueda et al
Poster: P4-02-01
Session Title: Detection/Diagnosis: Breast Imaging - Other Methods
Session Date: 9/12/16
Session Time: 7.30 - 9.00
Location: Hall 1
Abstract Name
Eribulin impairs TGFβ type I receptor localization and signaling in BT549 cells
Kaul et al
Poster: P4-04-04
Session Title: Tumour Cell and Molecular Biology: Epithelial-Mesenchymal Transition
Session Date: 9/12/16
Session Time: 7.30 - 9.00
Location: Hall 1
Abstract Name
Phase Ib/II study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
Tolaney et al
Poster: P5-15-02
Session Title: Treatment: Advanced Chemotherapy
Session Date: 9/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
A phase II study of eribulin as early-line treatment for HER2- MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes
Metzger et al
Poster: P5-15-08
Session Title: Treatment: Advanced Chemotherapy
Session Date: 9/12/16
Session Time: 17.00 - 19.00
Location: Hall 1
Abstract Name
Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumours of metastatic breast cancer patients. First preliminary report of a prospective study
Utsumi et al
Poster: P5-15-10
Werbung
Mehr Nachrichten zur Eisai Co Ltd Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
